Publication Name	World Journal of Gastroenterology
Manuscript ID	27510
Country	Italy

Received	2016-06-02 09:30
Peer-Review Started	2016-06-02 09:56
To Make the First Decision	2016-07-12 09:23
Return for Revision	2016-07-15 15:28
Revised	2016-08-02 17:01
Second Decision	2016-08-17 09:34
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2016-08-23 17:20
Articles in Press	2016-08-23 17:20
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-09-12 08:35
Publish the Manuscript Online	2016-10-12 14:18

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Hematology
Manuscript Type	Review
Article Title	Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma
Manuscript Source	Invited Manuscript
All Author List	Michele Merli, Giuseppe Carli, Luca Arcaini and Carlo Visco
Funding Agency and Grant Number
Corresponding Author	Dr. Carlo Visco, Department of Cell Therapy and Hematology, San Bortolo Hospital, Via Rodolfi 37, 36100 Vicenza, Italy. carlovisco@hotmail.com
Key Words	Non-hodgkin lymphomas; Hepatitis C virus; Antiviral therapy; Interferon; Ribavirin; Sofosbuvir; Direct-acting antiviral agents; Marginal zone lymphomas
Core Tip	In the last decade many clinical studies demonstrated that front line antiviral therapy (AT) with interferon (IFN) and ribavirin, is able to induce a 70%-75% response rate in patients with hepatitis C virus (HCV)-associated indolent non-Hodgkin lymphoma who do not need immediate conventional treatment. Hematological response was durable, and invariably related to the viral eradication. International guidelines indicate that AT should be the treatment of choice in such patients. Very preliminary data about the use of the new direct-acting antiviral agents (DAAs) suggest a similar activity in inducing lymphoma response. We discuss available literature about IFN-based AT and preliminary experiences with DAAs in the treatment of HCV-associated indolent lymphomas.
Publish Date	2016-10-12 14:18
Citation	Merli M, Carli G, Arcaini L, Visco C. Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma. World J Gastroenterol 2016; 22(38): 8447-8458
URL	http://www.wjgnet.com/1007-9327/full/v22/i38/8447.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i38.8447

Full Article (PDF)	WJG-22-8447.pdf
Full Article (Word)	WJG-22-8447.doc
Manuscript File	27510-Review.docx
Answering Reviewers	27510-Answering reviewers.pdf
Audio Core Tip	27510-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	27510-Conflict-of-interest statement.pdf
Copyright License Agreement	27510-Copyright assignement.pdf
Peer-review Report	27510-Peer-review(s).pdf
Scientific Misconduct Check	27510-Scientific misconduct check.pdf
Scientific Editor Work List	27510-Scientific editor work list.pdf